** Shares of vaccine maker Dynavax Technologies DVAX.O rise 1.8% to $14.26
** DVAX announces refinancing plan that extends the maturity of most of existing debt by four years
** Will issue $225 million of new convertible notes due in 2030
** New notes to replace about $185 million of existing convertible notes due in 2026, and an additional $40 million of new money will be raised
** New debt has a lower interest rate of 2% and a conversion price of $18.21/share; 30% premium to the stock's last close
** Co is buying back $8 mln of its own stock to keep the number of shares outstanding neutral
** DVAX to get $46.5 million from unwinding derivatives to partially offset the premium paid for the existing notes
** Co has 124.10 mln shares outstanding with a market cap of $1.7 bln - LSEG data
** DVAX fell 11.2% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。